Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deferitrin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Deferitrin (GT56-252) | DRUG | - |
| desferoxamine (DFO) | DRUG | - |
Inclusion Criteria: * Beta-thalassemia patients, 18 years of age or older, currently undergoing chronic blood transfusion therapy and iron chelation therapy who weigh more than 40 kg. * No clinically significant findings on physical exam, medical history, or screening laboratories. * Serum ferritin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | AGIO | 5 | PHASE3 | Mitapivat |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Luspatercept |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Etavopivat A, Etavopivat B, Etavopivat C |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN7999 |
| ICON Plc | ICLR | 1 | PHASE2 | SP-420 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
Deferitrin is an investigational small molecule being studied for the treatment of iron overload in patients with Beta-Thalassemia. It is designed to help manage transfusional iron overload, a common complication in this patient population. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Deferitrin is an iron chelator, a type of small molecule that binds to excess iron in the body to facilitate its removal. This mechanism is intended to address transfusional iron overload in patients with Beta-Thalassemia. The drug is being developed by Sanofi (SNY) and is currently in Phase 1 clinical trials.
Deferitrin is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is an investigational small molecule intended for the treatment of iron overload in patients with Beta-Thalassemia. It is currently in Phase 1 clinical development.
Deferitrin is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The drug is being studied for the treatment of iron overload in patients with Beta-Thalassemia, and its safety and efficacy have not yet been established.
Deferitrin has been studied in one completed Phase 1 clinical trial, identified as NCT00069862. This trial, titled "Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia," enrolled 25 participants in the United States. The study was uncontrolled and did not use randomization or blinding.
Deferitrin is also known as GT56-252, as indicated by the clinical trial NCT00069862, which studied both DFO and GT56-252 in patients with Beta-Thalassemia. This alternative name is used in research contexts to refer to the same investigational drug being developed by Sanofi.